IL10 Promoter Variants Are Associated with Gene Expression but They Are Not Markers of Susceptibility to Acute Coronary Syndrome

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 8

PMID 38851847

Authors

Texali Candelaria Garcia-Garduno

Jorge Ramon Padilla-Gutierrez

Maricela Aceves-Ramirez

Brenda Parra-Reyna

Hector Enrique Flores-Salinas

Emmanuel Valdes-Alvarado

Denisse Stephania Becerra-Loaiza

Antonio Quintero-Ramos

Iliannis-Yisel Roa-Bruzon

Andrea de la Cruz

Yeminia Valle

Affiliations

Soon will be listed here.

Abstract

Interleukin-10 (IL-10) is an immunomodulatory cytokine that plays a pivotal role in the pathogenesis of acute coronary syndromes (ACS). Here, we evaluated the role of IL10 promoter variants as markers for ACS susceptibility in Western Mexican patients as well as its association with IL10 mRNA and IL-10 plasma levels. Three promoter variants (- 1082 A > G, - 819 T > C and - 592 A > C) were analyzed in 300 ACS patients and 300 control group (CG) individuals. IL10 relative gene expression was evaluated in peripheral blood mononuclear cells (PBMC) and IL-10 levels were quantified in plasma. The allelic, genotypic and haplotypic frequencies did not show significant differences between groups. ACS patients had sevenfold higher mRNA IL10 level compared to CG (p = 0.0013). Homozygous C/C carriers in both - 819 T > C and - 592 A > C variants had 0.4-fold higher IL10 mRNA expression than heterozygous and polymorphic allele homozygous genotypes (p = 0.0357) in ACS group. There were significant differences in plasma IL-10 levels in CG and ACS group (1.001 vs 1.777 pg/mL, p = 0.0051). The variants were not markers of susceptibility to ACS in Western Mexican individuals. ACS patients showed higher IL10 expression than CG individuals which could be mediated by - 819 T > C and - 592 A > C variants and pharmacotherapy.

Citing Articles

Analysis of IL10 gene promoter haplotypes and changes in mRNA expression and soluble levels in patients with basal cell carcinoma.

Jimenez-Del Rio L, Zambrano-Roman M, Valdez-Salazar F, Valle Y, Munoz-Valle J, Padilla-Gutierrez J Arch Dermatol Res. 2025; 317(1):274.

PMID: 39825930 DOI: 10.1007/s00403-025-03806-x.

References

Kurreeman F, Schonkeren J, Heijmans B, Toes R, Huizinga T . Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet. 2004; 13(16):1755-62. DOI: 10.1093/hmg/ddh187. View

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A . Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis. 2012; 222(2):519-23. DOI: 10.1016/j.atherosclerosis.2012.03.016. View

van Tits L, Stienstra R, van Lent P, Netea M, Joosten L, Stalenhoef A . Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. Atherosclerosis. 2010; 214(2):345-9. DOI: 10.1016/j.atherosclerosis.2010.11.018. View

Cannon C, Brindis R, Chaitman B, Cohen D, Cross Jr J, Drozda Jr J . 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart.... Circulation. 2013; 127(9):1052-89. DOI: 10.1161/CIR.0b013e3182831a11. View

Cruz M, Fragoso J, Alvarez-Leon E, Escobedo-de-la-Pena J, Valladares A, Juarez-Cedillo T . The TGF-B1 and IL-10 gene polymorphisms are associated with risk of developing silent myocardial ischemia in the diabetic patients. Immunol Lett. 2013; 156(1-2):18-22. DOI: 10.1016/j.imlet.2013.09.007. View

Yu G, Cho H, Cho Y, Park H, Yoon H, Kim H . Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease. Inflamm Res. 2012; 61(8):899-905. DOI: 10.1007/s00011-012-0482-2. View

Lucero D, Islam P, Freeman L, Jin X, Pryor M, Tang J . Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis. Biochim Biophys Acta Mol Cell Biol Lipids. 2019; 1865(2):158537. PMC: 6993958. DOI: 10.1016/j.bbalip.2019.158537. View

Paolisso P, Foa A, Bergamaschi L, Donati F, Fabrizio M, Chiti C . Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA. Cardiovasc Diabetol. 2021; 20(1):33. PMC: 7856791. DOI: 10.1186/s12933-021-01222-9. View

10.

Wolinsky H . The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol. 1987; 10(10):561-6. DOI: 10.1002/clc.4960101010. View

11.

Vaduganathan M, Mensah G, Turco J, Fuster V, Roth G . The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022; 80(25):2361-2371. DOI: 10.1016/j.jacc.2022.11.005. View

12.

Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C . Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation. 2003; 75(5):711-7. DOI: 10.1097/01.TP.0000055216.19866.9A. View

13.

Posadas-Sanchez R, Angeles-Martinez J, Perez-Hernandez N, Rodriguez-Perez J, Lopez-Bautista F, Flores-Dominguez C . The IL-10-1082 (rs1800896) G allele is associated with a decreased risk of developing premature coronary artery disease and some IL-10 polymorphisms were associated with clinical and metabolic parameters. The GEA study. Cytokine. 2018; 106:12-18. DOI: 10.1016/j.cyto.2018.02.028. View

14.

Martinez-Cortes G, Salazar-Flores J, Fernandez-Rodriguez L, Rubi-Castellanos R, Rodriguez-Loya C, Velarde-Felix J . Admixture and population structure in Mexican-Mestizos based on paternal lineages. J Hum Genet. 2012; 57(9):568-74. DOI: 10.1038/jhg.2012.67. View

15.

Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad A . Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2014; 74(1):27-34. PMC: 4454631. DOI: 10.1016/j.cyto.2014.10.031. View

16.

Rai H, Joner M, Wilson H, McGovern L, Richards G, Colleran R . Interleukin-10 -1082 G/A polymorphism and its association with early or severe presentation of coronary artery disease: A systematic review and meta-analysis. Cytokine. 2022; 162:156103. DOI: 10.1016/j.cyto.2022.156103. View

17.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

18.

Borrayo-Sanchez G, Rosas-Peralta M, Ramirez-Arias E, Saturno-Chiu G, Estrada-Gallegos J, Parra-Michel R . STEMI and NSTEMI: Real-world Study in Mexico (RENASCA). Arch Med Res. 2019; 49(8):609-619. DOI: 10.1016/j.arcmed.2019.01.005. View

19.

Temple S, Lim E, Cheong K, Almeida C, Price P, Ardlie K . Alleles carried at positions -819 and -592 of the IL10 promoter affect transcription following stimulation of peripheral blood cells with Streptococcus pneumoniae. Immunogenetics. 2003; 55(9):629-32. DOI: 10.1007/s00251-003-0621-6. View

20.

Lutsey P . Case-control studies: Increasing scientific rigor in control selection. Res Pract Thromb Haemost. 2023; 7(2):100090. PMC: 10036796. DOI: 10.1016/j.rpth.2023.100090. View